

**CSUPERB's twenty-second annual  
CSU Biotechnology Symposium**

**Supplemental Program:**

**Graduate School Recruiting Session**

Friday, January 8<sup>th</sup>, 6pm-8pm

California Ballroom 6

**Career Networking Session**

Friday, January 8<sup>th</sup>, 2pm-4:30pm

California Ballroom 6



# Graduate School Opportunities

Friday, January 8<sup>th</sup>, 6-8pm *California Ballroom 6*

Students with biotechnology research project experience have many options for graduate school in business, science, engineering, medical and law programs. This two-hour interactive session is designed to allow students the opportunity to informally learn about a wide range of graduate school programs related to biotechnology. We've recruited 13 different universities to explain their graduate programs, admissions processes and give advice to CSU students this year.

Oftentimes career professionals take time off between their degrees and work to gain perspective and experience before entering graduate school. Many employers have tuition reimbursement benefits that allow you to take coursework while employed. Of note, many scientific doctoral programs cost students very little in tuition and fees because students are supported by grant funding. Even if you don't plan at this point on entering graduate school, these recruiters can educate you about your options for the future.

The session will allow you to explore and roam freely between different programs. Sit down and talk to the recruiters and ask questions! Find below a list of participating graduate programs.

## Speakers:

Jennifer Lillig, Sonoma State University

Mallika Keralapura, San Jose State University

## *Participating Graduate School Programs:*

**California State University, Channel Islands** MS in  
Biotechnology and MBA Dual Degree

**Stanford University School of Medicine**  
Biosciences PhD programs

**California State University Fullerton, Los Angeles, Pomona**  
Program for Applied Biotechnology Studies

**University of California, Davis**  
Office of Graduate Studies

**Keck Graduate Institute of Applied Life Sciences**

**University of California, Irvine**  
Graduate Division

**San Diego State University**  
Computational Science Research Center

**University of California, Los Angeles**  
Graduate Division

**San Francisco State University**  
Professional Science Masters Program

**University of California, San Diego**  
Office of Graduate Studies

**San Jose State University**  
Professional Science Master of Biotechnology Program

**Washington University in St. Louis**  
Division of Biology and Biomedical Sciences

**Santa Clara University**  
Leavey School of Business

# Career Networking Session

Friday, January 8<sup>th</sup>, 2-4:30pm *California Ballroom 6*


Students in life sciences degree programs should know that there are many career tracks available to them. This two and half hour interactive career networking session is designed to allow students the opportunity to informally learn about a wide range of career tracks in the life sciences. We've recruited over 30 expert mentors, including scientists, business development experts, quality assurance and regulatory affairs professionals, and for the first time we even have mentors from the Food and Drug Administration (FDA) and mentors in Clinical Laboratory Sciences to help explain career tracks, relate their own experiences, give advice and answer questions. Even if you don't plan at this point on following a particular career path, these mentors will inspire and educate you about career opportunities in the life sciences.

The session will provide you with an opportunity to gain knowledge and skills to help you find a job in today's economic environment.

The session will allow you to rotate to four different tables at 30 minute intervals. There will be a total of 18 tables and each can accommodate 1-2 experts and about 10 students. Students must sit at a table – you cannot 'lurk' or 'surf' between tables! You might find yourself at a table not of your own choosing – but we guarantee that each and every mentor present has something to teach you or can answer questions about careers in the life sciences industry.

Descriptions of each table are listed below so that you can read ahead about each table and know who you might meet at the Career Networking Session.

A special thanks to our table sponsors:



## **PLANNED SESSION SCHEDULE:**

2:00pm Welcome – Lori Lindberg, Director of Workforce & Education, BayBio

2:15–2:45pm Table Rotation #1

2:50-3:20pm Table Rotation #2

3:25-3:55pm Table Rotation #3

4:00-4:30pm Table Rotation #4

## Invited Speaker:

**Lori Lindburg** is the Director of Workforce & Education at BayBio Institute. She currently manages the BayBio Institute's workforce and education initiatives, ensuring that they align with industry needs. With over 9 years of experience in workforce development, Lori has worked with the private sector, local governments and organizations to develop workforce systems in growth industries that are inclusive of underserved communities. During her 8.5 years as VP of SF Works, Lori led employer engagement efforts and developed and managed SF Works' pre-employment training programs, including the nationally-recognized On-Ramp to Biotech program. Having completed coursework for a Ph.D. at American University in Washington, D.C., Lori served as a Senior Research Associate at the Brussels-based Migration Policy Group for 5 years, where she coordinated best practice exchanges between business leaders and senior officials from the EU member states, the US and Canada. She has also served as a Visiting Fellow at Stanford University, a Research Associate at the Carnegie Endowment for International Peace, and a consultant for the Council of Europe.

### **TABLE 1: FINDING A JOB IN TODAY'S ECONOMY**

With record unemployment and a weak economy, finding a job in today's market can be tough. But this does not mean it can't be done! Learn from industry recruiters the tools and techniques you need to increase your chances of finding a job.

**Heather Keller**, Lab Support

**Niki Manalo** is a Sr. Account Executive at Lab Support. Niki has six years of experience working for a consumer products company. She has been involved with new product development, idea generation, prototype development, product formulation, product performance testing and Stability Studies in a GLP environment. Niki has three years of experience in the scientific staffing industry. She is a BayBio volunteer, Palo Alto AWIS member and CACO member. She has a BS in Chemical Engineering from UC Berkeley and a MS Engineering Management from Santa Clara University.

### **TABLE 2: HOW TO APPLY/INTERVIEW**

First impressions can go a long way, especially when trying to land a job. You need to be thoughtful when developing your application, and articulating your skills to potential employers. Get advice and tips from industry experts to set yourself apart from competition and improve your job search results.

**Nicole Culligan**, Talent Acquisition Manager, Abbott Vascular

**Toby Freedman** is an author and Founder/President of Synapsis Search. A scientist by training, she transitioned into business as a recruiter, writer, and entrepreneur. Her book *Career Opportunities in Biotechnology and Drug Development* was published in October 2007 by Cold Spring Harbor Laboratory Press, and provides a comprehensive overview of many careers in the life sciences industry. She recently started her own recruiting firm, Synapsis Search, which is focused on executive R&D and business placements in the life science industry.

She previously worked at BioQuest, an executive search firm, placing VP to CEO-level executives, and as Director of Business Development at SLIL Biomedical, a drug discovery company developing therapeutics for cancer and other diseases. She earned a Ph.D. in molecular biology from UNC Chapel Hill, a B.S. from the University of California, and as an NIH Fellow, conducted postdoctoral research at Harvard University and at the University of Texas-Austin.

**Maggie Wong**, Senior Recruiter, Abbott Vascular

### **TABLE 3: MEDICINAL CHEMISTRY**

Medicinal Chemistry is a multifaceted discipline that encompasses synthetic organic chemistry, natural products chemistry, enzymology, chemical biology, structural biology and computational methods, all of which are aimed at the discovery and development of new therapeutic agents. Medicinal chemistry is by nature an interdisciplinary science, and practitioners have a strong background in organic chemistry, coupled with a broad understanding of biological concepts related to drug targets. Scientists in the field are well positioned to work as part of an interdisciplinary team that uses chemical structural principles to design effective drugs and diagnostic agents.

**Daniel E. Levy** is an organic/medicinal chemist and holds a PhD in organic chemistry from the Massachusetts Institute of Technology. Since 1992, he has contributed to drug discovery programs targeting inflammatory, cardiovascular and oncologic indications. His work is documented in numerous patents and peer reviewed journals. In addition to his industrial activities, Dr. Levy has taught short courses and authored books on various aspects of carbohydrate and mechanistic organic chemistry. He is currently the Director of Synthetic Chemistry at Intradigm Corporation pursuing novel delivery vehicles for therapeutic siRNAs.

**David Smith**, Principal Research Scientist, Roche

### **TABLE 4: CLINICAL TRIALS MANAGEMENT**

#### **TABLE SPONSOR: ABBOTT VASCULAR**

Before drugs and biodevices are approved for sale, they are extensively tested in preclinical and clinical trials to prove to regulatory agencies, like the Food Drug Administration (FDA), that they are safe and effective. The clinical trials management process involves regulatory experts, biostatisticians, project manager, medical professionals, pharmacists and outreach coordinators at all degree levels.

**Anthony Puthumana** is a Clinical Project Manager at Abbott Vascular, currently involved in the management of multiple clinical trials involving coronary drug-eluting stents. He is in his second year working at Abbott, and had previous involvements in the clinical, medical device, and start-up space.

**Kunal Sampat** joined Abbott Vascular as a Clinical Project Manager in 2007. In his current role, Kunal is responsible for managing drug eluting stent clinical trials in Japan. As a clinical project manager, he has extensive training and certification in managing clinical trial resources, budgets and timelines. In 2008, His work led to FDA approval of the Xience V™ stent. Prior to

joining Abbott, Kunal worked as a project lead at Parexel International and served as a research volunteer at the Boston Medical Center. Currently, Kunal is pursuing a Masters in Non-Profit Administration at University of San Francisco, California. In June 2009, he completed the Biodesign certificate program from Stanford University. Kunal holds a Bachelors degree in Computer Science and Electrical Engineering with Honors from University of Massachusetts, Lowell.

#### **TABLE 5: INTELLECTUAL PROPERTY MANAGEMENT**

As scientists and technologists make novel discoveries, intellectual property is created. Intellectual property management refers to the activities involved in protecting or transferring these discoveries with commercial potential. Lawyers, scientists, patent agents and business experts' work together to disclose innovations, file patents, and license rights.

**Henry Heines**, Ph.D., has over thirty years of experience prosecuting patents and rendering analyses in patent cases, Dr. Heines has a vast knowledge of such diverse areas as organic and inorganic chemistry, chemical engineering, mechanical engineering, biotechnology and medical devices. His practice further extends to nanotechnology as applied to drug delivery systems, metal alloy microstructures, and ceramics, including inventions involving carbon nanotubes. Although his practice is concentrated in patent prosecution, he often provides litigation support for patent litigators, including detailed patentability, validity and infringement studies. Dr. Heines works directly with engineers and scientists as well as in-house counsel in preparing and obtaining patents for clients in the United States and abroad. He also prepares patent, trade secret and technology transfer licenses and confidentiality agreements for his clients.

**James M. Ritchey**, J.D., Ph.D., (Registered Patent Attorney No. 32,594) attended the University of Redlands (B.S. in Chemistry, 1969), Northwestern University (M.S. and Ph.D. in Biochemistry, 1971 and 1974, respectively), and the University of the Pacific, McGeorge School of Law (J.D., 1985). Additionally, from 1974 to 1977 he was a Post Doctoral Fellow (NIH) in the Department of Molecular Biology, UC, Berkeley. Jim is now in his 32nd year as a professor of chemistry/biochemistry at CSU, Sacramento and for 15 years was an adjunct professor at McGeorge School of Law, teaching intellectual property law and patent law. He is a partner at O'Banion & Ritchey LLP ([www.intellectual.com](http://www.intellectual.com)) which specializes in intellectual property law (patents, trademarks, copyrights, trade secrets, and unfair competition) and related litigation and licensing matters. In his patent practice Jim concentrates on patent prosecution relating to chemistry, biochemistry, molecular biology, and computer-interfaced mechanical systems.

#### **TABLE 6: DISCOVERY RESEARCH**

##### **TABLE SPONSOR: AMGEN**

Science and technology discoveries lead to new products, medicines and diagnostics aimed at improving human health, but product development takes a relatively long time in comparison to other industries. Discovery research involves multi-disciplinary teams of scientists, engineers and project managers, at all degree levels, working together to find novel solutions or technical innovations that will impact human health. Most of the early stage discovery research is still done in academic institutes then these discoveries are out-licensed for commercialization.

**Alexander Kamb** received his A.B. from Harvard University and his Ph.D. from Caltech. After a postdoctoral fellowship at UCSF, he worked in the biotechnology field for about ten years, specializing in the genetics of cancer, and then in the Pharmaceutical sector where he led the Novartis Oncology Research Group. In 2006, Dr. Kamb joined Amgen to direct Oncology Research at their South San Francisco site. In 2007 he took over the leadership of the Neurosciences Therapeutic Area.

**Helen Kim** received her Ph.D. from the Molecular biology Institute, at UCLA, in 1995, where she studied gene regulation in neural development under the guidance of Allan Tobin. Dr. Kim then received postdoctoral training at the Department of Pharmacology, UCLA, where she continued her research on regulation and function of neurotransmitter receptors during development and in epileptogenesis. Upon joining the Protein Science Department, Amgen, in 2000, Dr. Kim led a group of scientists whose main focus included molecular biology, vector development, protein engineering, assay development, and mammalian cell line development for expression of recombinant proteins and antibody molecules, thus contributing to numerous Amgen Discovery Research programs as well as Clinical programs. Dr. Kim joined the Dept of Chemistry Research & Discovery in 2008, and her current role is to provide a multi-site leadership for Amgen Lead Discovery Groups at Amgen South San Francisco, and Amgen Washington.

#### **TABLE 7: BIODEVICE PRODUCT DEVELOPMENT**

Biodevice developers must continually address issues of miniaturization, biocompatibility and safety. The regulatory approval process for biodevices is different than for pharmaceuticals and biologics.

**Mark Dolan** is a Principal Engineer at Medtronic. Mark has over 10 years of experience in the medical device industry. He has been involved with many of the steps to develop a product for market. From an engineering perspective, he has developed new manufacturing methods, designed new products, and created a new therapy that is currently in clinical trials. As an inventor, he has had four US patents issued and 30 patent applications filed in fields ranging from vascular stenting to urology. Mark has a BS in Mechanical Engineering from UC Santa Barbara, and is currently, pursuing a post graduate degree at USC.

**Robert Goldman**, CEO, Vascular Designs

#### **TABLE 8: QUALITY AND REGULATORY AFFAIRS**

##### **TABLE SPONSOR: ORANGE COUNTRY REGULATORY AFFAIRS DISCUSSION GROUP (OCRA)**

Professionals in quality and regulatory affairs departments facilitate and manage the process of getting FDA approval for new products. Experts in these functional areas may also negotiate and work directly with regulatory agencies and health authorities.

**Liz Alison** is an independent regulatory affairs and compliance consultant. She has over 20 years experience in the IVD industry, most recently working with early stage companies on cutting-edge diagnostics. These assignments have included working with and advising teams on the development of assay and instruments for SNP, gene expression and protein biomarker

assays, including IVDMIAs. Prior to setting up her own consultancy company, she was VP of Regulatory Affairs at Aviir, Director of Regulatory Affairs at XDx, VP of Operations at Naxcor and VP of Customer Service Operations at PharmChem. She also held a number of sales and product management positions at Syva UK. Liz has a BS in Medical Science from Bradford University, UK.

**Aleisha Dobbins**, Senior Specialist, Clinical Quality & Training, BioMarin

**Kim Walker**, MS, RAC is an independent Global Regulatory Affairs and Quality Assurance Consultant. Her work experience includes environmental chemistry, veterinary science, blood banking, microbiology, IVDs, biologics, pharmaceuticals, combination products, and medical devices in both start-up and large company environments. Kim has served on the Orange County Regulatory Affairs Discussion Group (OCRA) Program Committee since 2003. Additionally, she has served on the OCRA Board of Directors since 2004 and is the 2008-2009 President. Kim actively participates on the CLSI Point of Care Testing, Quality Systems, EP9, and Process Improvement working groups. She has received both the US and EU RAPS certifications. She graduated from Auburn University with a Bachelor of Science degree in Bio-Medical Sciences and graduated with a Master of Science degree in Regulatory Affairs from San Diego State University.

#### **TABLE 9: PRODUCT DEVELOPMENT**

There are many aspects involved in product development from the initial design phases through testing to successfully turn biotechnology developments into marketable products. This has to be aligned with FDA requirements for approval process from the beginning to avoid costly delays or outright rejections.

**Kate Farrell**, Business Development Executive, Epistem

**Ken Hitchner** is Vice President of Pharmaceutical Collaborations at Monogram Biosciences. He joined Monogram as Director of Project Management in May 1999 and was named Vice President of Pharmaceutical Collaborations in October 2003. From December 1997 to May 1999, Mr. Hitchner was the Director of Project Management at Gilead Sciences. Prior to Gilead, he was with Genentech for 15 years and held a number of positions including Director of Product Development and Global Project Leader. Mr. Hitchner received his bachelor's degree in zoology from DePauw University and a master's degree in biology from San Francisco State University.

#### **TABLE 10: BUSINESS DEVELOPMENT**

Business development professionals are involved in range of activities including strategy and market planning, new business development, and licensing (key). Some business development professionals are engaged in technology transfer at universities and work with scientists to commercialize their inventions with industry partners.

**Nathalie Dubois-Stringfellow**, Sr. Director Business Development, Xoma

**Karin Immergluck** is a Senior Licensing Officer at UCSF Office of Technology Transfer. Karin rejoined the Office of Technology Management at UCSF in June 2004, following 2 ½ years as a

Licensing Officer at the Office of Technology Transfer in the UC Office of the President in Oakland, and one year previous to that as a part-time Licensing Intern at the OTM. She is responsible for technology management, licensing and outgoing material transfer agreements. While at the OTT, Karin managed a large life-sciences portfolio consisting of technologies from seven of the UC campuses. Her activities included managing patent interferences, infringement issues and other licensing-related disputes. She received a M.S.-equivalent degree in biochemistry from the University of Zurich in Switzerland.

### **TABLE 11: ENGINEERING**

Biomedical engineering combines the design and problem solving skills of engineering with medical and biological sciences to improve healthcare diagnosis and treatment.

**Bob Bettis**, Hyde Engineering + Consulting

**Simon Forder** is President and Chief Executive Officer for Hyde Engineering + Consulting, where he is responsible for strategic leadership and growth of the organization. In addition to his leadership responsibilities, Simon is responsible for developing and executing sales strategy, business development and driving the company's growth. Simon joined Hyde Engineering + Consulting (Hyde) in 2003 and was responsible for opening and developing West Coast operations in South San Francisco and San Diego. Responsibilities included overseeing engineering and validation programs for a number of biopharmaceutical manufacturing companies. Prior to joining Hyde, Simon held the role of Process Development Project Manager with Nektar (formally Inhale Therapeutic Systems), a pharmaceutical research and manufacturing company located in San Carlos, CA. Mr. Forder holds a Bachelor's degree in Fermentation Science from the University of California at Davis.

### **TABLE 12: FOOD & DRUG ADMINISTRATION (FDA)**

The United States Food and Drug Administration is the government agency responsible for regulating food, dietary supplements, drugs, cosmetics, medical devices, biologics and blood products in the United States.

**David Lau** is a Commissioned Officer with the US Public Health Services. Currently, CDR Lau is the Supervisory Senior Regulatory Research Officer in the FDA San Francisco District Laboratory. CDR Lau received his Bachelors in Microbiology at University of California, Berkeley and a Masters in Molecular Biology at San Francisco State University where he also received a Certificate in Genetic Engineering. He joined the FDA in 1991. He has been the recipient of FDA's Long Term Training, SARAP (Science Advisor's Research Associate Program) project, and FDA's Leadership Development Program. CDR Lau's work includes participation in collaborative studies and validation studies, foreign inspections, and method development. He has worked on isolation and detection methods for *Helicobacter pylori*, *Listeria monocytogenes*, *Shigella sp.*, and *Cryptosporidium parvum*. CDR Lau is also a trainer for FDA's National Courses on Mobile Laboratories, Fundamental of Regulatory Science, Biosafety Level 3 Practices, and Evidence Development.

**Mary Ellen Taylor** has been employed by the Food and Drug Administration as a Public Affairs Specialist for twelve years. Prior to employment with the FDA, Mary Ellen served as a Health

and Nutrition volunteer in the Peace Corps in Guatemala. She received a Masters of Science Degree in Public Health from Tulane University and an undergraduate degree in Psychology from the University of Arizona. Mary Ellen serves as a member on the Health Fraud Task Force of California. She is a past member of the Association of Food and Drug Officials Editorial Board and a past Co-editor of the Western Association of Food and Drug Officials' quarterly publication, the *Flash*.

### **TABLE 13: MEDICAL MARKETING**

Marketing activities in the life sciences industry include science or technology education, public relations and communication, market analysis, product branding, and strategic planning. Unlike other industries, this is highly FDA regulated.

**Susie Faries** is CEO of SciMed Partners, which helps established companies, potential investors, and entrepreneurs assess markets, technologies, and intellectual property in the scientific and medical arenas. SciMed focuses on medical devices, medicine, biotechnology, pharmaceuticals, and emerging technologies. Susie has held senior executive level positions with major US corporations including Vice President of Marketing for American Medical Response, the largest provider of emergency medical services in the US (\$1 billion in revenue) and Vice President of Marketing for American Medical Pathways, the technology subsidiary of American Medical Response. She is the former CEO of SMS Healthcare, headquartered first in Virginia then Denver, with offices in North Carolina and West Virginia.

**Diane Heditsian**, Executive Creative Director, deClarity

**Kelly Seither**, Sr. Director, New Product Planning, Alexza Pharmaceuticals

### **TABLE 14: CLINICAL LABORATORY SCIENCES**

Clinical Laboratory Scientists play a critical role in the detection, diagnosis and treatment of diseases. California currently faces an acute shortage of certified Clinical Laboratory Scientists (CLS's) needed to meet the immediate and growing workforce need within both the allied health and life science industries.

**Kim Dickinson**, Medical Director, US Labs

### **TABLE 15: HEALTH IT**

Health IT involves the management of health information and its secure exchange between consumers, providers, government and quality entities, and insurers. Health information technology is increasingly being viewed as the most promising tool for improving the overall quality, safety and efficiency of the health delivery system.

**Lynn Barr** is a Consultant to the Deputy Secretary of Health Information Technology at California Health and Human Services. Lynn is a seasoned entrepreneur who has led four health technology and information companies. She is currently coordinating the Regional Extension Center program for the State of California whose goal is to assist 10,000 providers in the adoption and meaningful use of Electronic Health Records in the next two years.

**Bill Beighe**, Chief Information Officer, Physicians Medical Group of Santa Cruz

**TABLE 16: PHARMACEUTICAL MANUFACTURING**

Small molecule drugs, biotherapeutics, and medical devices must be repeatedly manufactured in large enough quantities, without unsafe impurities, to be safe on the market. To ensure the safety and quality of the supply chain, biomedical scientists, engineers, regulatory experts, project managers, and analytical chemists work together in pharmaceutical manufacturing groups.

**Brett Goldsworthy** is a Senior Associate, Manufacturing at Amgen. Brett received a BS in Animal Biotechnology from US Davis in 2005 and worked for UC Davis as a research associate from 2004 until 2006. He has been working at Amgen's Fremont site since 2006 and is currently a lead technician in the cell culture department. The department is responsible for executing the large scale cell culture operations necessary for the production of Vectibix (a monoclonal antibody used for the treatment of metastatic colorectal cancer).

**Eric Richardson** is a Senior Associate, Manufacturing at Amgen. Eric graduated in 2006 from the University of California - Berkeley majoring in Molecular and Cell Biology. Upon graduation he started working at Amgen Fremont in a contract position in support of Manufacturing. After 7 months in this role, he accepted a full-time position at AFR in the Manufacturing Purification department. He worked on the production floor for approximately a year and half, and then transitioned into the Production Process Owner position that he currently works in today. In this role he serves as the conduit between Manufacturing and the numerous other departments at AFR to improve efficiency, implement changes, and troubleshoot issues.

**TABLE 17: BIOINFORMATICS**

With the availability of genomic information, relatively cheap computing and storage, high throughput screening methods and large clinical datasets, the biological sciences are increasingly becoming an information science. Using statistical methods, algorithms, databases and other mathematical methods, informaticians sift through data for signals and predict outcomes for a wide variety of biological data types to help drive discovery research, make product development more efficient and assess product safety post approval.

**David Spellmeyer** joined Nodality in September of 2006. Prior to Nodality, he held positions as a research staff member in the IBM Almaden Services Research group, as chief scientific officer and vice president of drug discovery at Signature BioSciences, as executive director at DuPont Pharmaceuticals, as vice president at CombiChem, and a principal scientist at Chiron. Dr. Spellmeyer received his Ph.D. in 1987 from UCLA, and completed his post-doctoral work in pharmaceutical chemistry at UCSF. He continues his interaction with the UCSF research groups through his adjunct associate professorship. He has authored more than 35 scientific publications, and frequently makes presentations at scientific seminars.

### **TABLE 18: START UP A COMPANY**

Have you ever contemplated starting up your own company? It can be kind of exciting, have its share of challenges but is definitely do-able. Learn from our industry mentors that have started companies what it takes to successfully start up a company.

**David DeNola** is a life sciences/biotech professional with 3 decades of experience in start-ups and emerging companies. He has a proven track record in long term strategy development and leadership of complex capital investment projects as well extensive operational experience in all phases of starting and growing companies. His operational experience extends to medical devices, biophotonics, mammalian cell culture reagents, plant biotechnology, *in vitro* molecular diagnostics; stem cell therapeutics, protein/antibody purification & production; proteomics; pharmaceutical contract manufacturing; biofuels development and scale-up. David believes in the importance of preserving a culture of innovation, while building flexible infrastructure for growth.

**Peter Matlock** has 25 years experience in Biotechnology business development, licensing and entrepreneurship. He co-founded three biotechnology companies: Bioren (directed mutagenesis for therapeutic antibodies, acquired by Pfizer). Ventria Biosciences (first-generation molecular farming) and Viridis (pioneering biocatalysis/green chemistry). Business development experience includes therapeutics/drug development (Lipomics, Creative BioMolecules/Curis, Vitalea), agriculture (Seminis; Calgene) and industrial biotechnology (metabolic engineering/green chemistry clients). Mr. Matlock focuses on commercializing advanced research technology, including technology transfer at the Stanford and LLNL offices of technology licensing. Mr. Matlock's education includes a BA, Swarthmore College and graduate degrees in Management Science and Technology, Stanford University.